Guildford, UK, 5 June 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will participate in the European Stem Cells & Regenerative Medicine Congress 2006 at the Jumeirah Carlton Tower Hotel, London on June 5-7.
Michael Hunt, Chief Executive Officer of ReNeuron, will present an overview of the Company’s technology and ReN001 stroke programme, and participate in a panel discussion concerning the commercialisation of stem cell technologies, scheduled for 14:00 BST on 7 June.
More information about the conference may be found at www.lifescienceworld.com/2006/stemcells
Notes to editors
About ReNeuron Group plc
ReNeuron is a leading, UK-based adult stem cell therapy business. The Company is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs.
ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.
The Company’s lead stem cell therapy, ReN001 for chronic stroke disability, is in late pre-clinical development. Subject to successful completion of pre-clinical testing, the Company plans to file for approval to commence initial clinical trials in stroke later this year, with trials commencing as soon as possible thereafter.
The Company has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington’s disease, a rare, genetic and fatal neurodegenerative disorder which affects around 1 in 10,000 people. This programme is in pre-clinical development.
In addition to its stroke and Huntington’s disease programmes, ReNeuron is developing stem cell therapies for Parkinson’s disease, Type 1 diabetes and diseases of the retina.
ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas – its ReNcellTM range of cell lines for use in drug discovery applications in the pharmaceutical industry.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L, and its warrants are traded under the symbol RENW.L.
Further information on ReNeuron and its products can be found at www.reneuron.com.
Michael Hunt, Chief Executive Officer
Tel: +44 (0) 1483 302560
Tel: +44 (0) 20 7831 3113
The terms “ReNeuron” or “the Company” refer to ReNeuron Group plc and its subsidiary undertakings.